SGLT2i

4 · 20 / page

Ask MedXY AI

Latest news

Tag

CardiologyGLP-1RAHội Chứng CKM

The Cardiovascular-Kidney-Metabolic (CKM) Syndrome Revolution: Mapping Medication Eligibility and Multi-Systemic Benefits

By MedXY|Mar 28, 2026

This review synthesizes recent evidence on the massive scale of CKM medication eligibility in the US, the synergistic effects of pharmacotherapy with lifestyle, and emerging neuropsychiatric benefits of GLP-1 receptor agonists.

The Rising Tide of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Synthesis of Medication Eligibility and Clinical Implementation

CardiologyGLP-1RAHội Chứng CKM

SGLT2i

Latest news

The Cardiovascular-Kidney-Metabolic (CKM) Syndrome Revolution: Mapping Medication Eligibility and Multi-Systemic Benefits

The Rising Tide of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Synthesis of Medication Eligibility and Clinical Implementation

SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes: A Comparative Effectiveness Review

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study